E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10063001 |
E.1.2 | Term | Human papilloma virus infection |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the anti-HPV 6, 11, 16, and 18 levels generated following administration of a 3-dose regimen of GARDASIL™ up to 10 years postdose 3. |
|
E.2.2 | Secondary objectives of the trial |
To estimate the long-term effectiveness of GARDASIL™, when administered to 9- to 18-year-old girls, with respect to the combined incidence of persistent HPV 6, 11, 16, and 18 infection and HPV 6-, 11-, 16-, and 18-related CIN, AIS, VIN, VaIN, genital warts, and cervical/vaginal/vulvar cancer. (2) To estimate the long-term effectiveness of GARDASIL™, when administered to 9- to 18-year-old boys, with respect to the combined incidence of persistent HPV 6, 11, 16, and 18 infection and HPV 6-, 11-, 16-, and 18-related PIN, genital warts, and penile/perineal/perianal cancer. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Healthy adolescents and preadolescents (9 Years to 15 Years Old) with no prior sexual history |
|
E.4 | Principal exclusion criteria |
Subjects with compromised immune system or have a history of severe allergic reaction
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Immunogenicity endpoints:
Serum geometric mean titers (GMTs)
Seropositivity rates to HPV 6, 11, 16, and 18.
Effectiveness Endpoints
Female Endpoint:
Persistent HPV infection
External Genital Warts, VIN, VaIN, and/or vulvar or vaginal cancer related to HPV 6,11, 16, or 18
External Genital Warts, VIN, VaIN, and/or vulvar or vaginal cancer related to HPV 6,11, 16, or 18
CIN, AIS, and/or cervical cancer related to HPV 6, 11, 16, or 18
Male Endpoint:
Persistent HPV infection
External genital warts, PIN, or penile/perineal/perianal cancer related to HPV 6, 11,16, or 18
Safety Endpoints
GARDASIL™ Related SAE
Study Procedure SAE
Death
Pregnancy |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The long-term follow-up period will start 6 months after the completion of the last Protocol V501-018-05, 06 visit (i.e., Month 42) and end at Month 126 (approximately 7.5 years later).
|
|
E.5.2 | Secondary end point(s) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
Colombia |
Mexico |
Taiwan |
Thailand |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 12 |